Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01384994
Other study ID # PARLIM
Secondary ID
Status Recruiting
Phase Phase 2
First received May 2, 2011
Last updated July 5, 2012
Start date August 2011
Est. completion date August 2014

Study information

Verified date July 2012
Source Ludwig-Maximilians - University of Munich
Contact Volker Heinemann, Prof. Dr. med.
Phone +49 89 7095
Email volker.heinemann@med.uni-muenchen.de
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

Up to 50% of patients with colorectal cancer (CRC) develop liver metastasis during the course of their disease. In 30-40% of patients metastasis is confined to the liver. In these patients R0-resection of metastases may contribute to marked improvement of overall survival. Primary resection of liver metastasis is possible in about 15-20% of patients (Scheele 2005, Petrelli 2005). Recent studies indicate that perioperative chemotherapy may improve survival after resection of liver metastases (Portier 2007, Nordlinger 2007). Nevertheless, there is evidence that 70-80% of patients have recurrent disease after resection of liver metastasis. Stratification for the risk of recurrence may be performed using the FONG-score (Fong 1999).

This study is designed to investigate the efficacy of postoperative chemotherapy combined with an anti-EGFR treatment using panitumumab.

The majority of patients present to the surgeon after chemotherapeutic pretreatment with various not necessarily standardized regimens. Also postoperative therapy after resection of liver metastasis is not a clearly defined standard of care in Germany.

Based on the study by Nordlinger et al. an oxaliplatin-based regimen is chosen for postoperative therapy (Nordlinger 2008). For reasons of practicability mFOLFOX6 was selected as the chemotherapy backbone for additive treatment (Allegra 2010).

Also, there is evidence that the combination of FOLFOX with panitumumab is associated with enhanced antitumor activity (Douillard et al. ESMO 2009). The experimental treatment arm will therefore evaluate the combination of FOLFOX plus panitumumab. Since in colorectal cancer monoclonal antibodies directed against the EGFR are not active in KRAS mutant patients, the experimental arm including panitumumab will only be performed in KRAS wild-type patients (Amado 2008).

The planned study aims to assess the efficacy of postoperative therapy with FOLFOX plus panitumumab followed by maintenance with panitumumab for 3 months in KRAS wild-type patients, compared to the historical data for standard FOLFOX chemotherapy alone, which are verified by a randomised control group without the antibody. (Figure 1: Study Design).

The study will allow preoperative treatment with regimens such as FOLFIRI, XELIRI, FOLFOX or XELOX +/-bevacizumab or +/- cetuximab. However, only those patients will be considered eligible who did not progress during preoperative therapy.

After surgery, a treatment-free interval of at least 4 weeks, but no longer than 8 weeks will be granted.

KRAS-wild-type patients (60% of all pts) will then be randomized in a 2:1 ratio to an experimental arm with FOLFOX + panitumumab or to a reference arm with FOLFOX alone. Combination treatment will be performed for a duration of 3 months, after which patients in the experimental arm will receive maintenance therapy with panitumumab for further 3 months. In the reference arm, treatment will, however, be ended after 3 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 111
Est. completion date August 2014
Est. primary completion date August 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient has provided written informed consent.

- R0-resection of liver metastasis, at least four weeks but not longer than 8 weeks ago.

- Histologically confirmed diagnosis of metastatic colorectal cancer confined to the liver

- KRAS-wildtype of the tumor

- Age 18 years or older

- ECOG performance status 0-1

- Females with child-bearing potential must use adequate contraceptive measures

- Exclusion of pregnancy

- Relevant toxicities of previous treatments must have subsided

- Magnesium >= lower limit of normal; Calcium >= lower limit of normal

- Normal cardiac function demonstrated by ECG and echocardiogram (LVEF = 55%)

- No symptomatic congestive heart failure

- No unstable angina pectoris

- No cardiac arrhythmia

- Adequate organ function as defined by Table 1:

- Hematologic: ANC (absolute neutrophil count) >= 1.5 G/L, Leucocytes > 3.0 G/L, Hemoglobin >= 9 g/dL, Platelets >= 100 G/L

- Hepatic: Albumin >= 2.5 g/dL, Serum bilirubin <= 2 mg/dL, AST and ALT <= 3 x ULN

- Renal: Serum Creatinine <= 1.5 mg/dL

Exclusion Criteria:

- Known manifestations of metastatic disease

- Progression during preoperative treatment

- Missing KRAS mutation status of the tumor

- Contraindication against therapy with 5-fluorouracil/ folinic acid or oxaliplatin

- Known intolerability of panitumumab

- Known DPD deficiency

- Polyneuropathy > grade 1 (NCI-CTCv4) which precludes the use of oxaliplatin

- Evidence of ascites or cirrhosis

- Patient is pregnant or lactating or planning to become pregnant within 6 months after end of treatment

- Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment

- Has had a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrolment, or there is an anticipated need for major surgical procedure during the course of the study

- Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) <= 1 year before enrolment/randomization

- History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan

- Has a concurrent disease or condition that would make the subject inappropriate for study participation or would interfere with the subject's safety.

- Has any psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.

- Requires concurrent cancer therapy (chemotherapy, radiation therapy, biologic therapy, immunotherapy, or hormonal therapy) while on study.

- Requires concurrent treatment with an investigational agent, participation in another clinical trial, or any specifically prohibited medication while on study.

- Has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to 5-fluorouracil, folinic acid, oxaliplatin, or panitumumab.

- Other active malignancy

- Known alcohol abuse or drug addiction

- Incapability to give informed consent

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Folic Acid
400 mg/m2, 2h infusion, d1, q2w
5-FU
400 mg/m2 bolus iv, d1, q2w
5-FU
2400 mg/m2 46-h infusion, d1-2, q2w
Oxaliplatin
85 mg/m2 d1, q2w
Panitumumab
6 mg/kg BW every 2 weeks
Panitumumab
Panitumumab maintenance phase (3 months) 9mg/kg BW every 3 weeks
Folic Acid
400 mg/m2, 2-h infusion, d1, q2w
5-FU
400 mg/m2 bolus iv, d1, q2w
5-FU
2400 mg/m2 46-h infusion, d1-2, q2w
Oxaliplatin
85 mg/m2 d1, q2w

Locations

Country Name City State
Germany Ludwig-Maximilians - University of Munich Munich

Sponsors (2)

Lead Sponsor Collaborator
PD Dr. med. Volker Heinemann Amgen

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival 2 years after randomisation No
Secondary Tolerability and side effects approximate 6 months after randomisation Yes
Secondary Overall Survival 2 years after randomisation No
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A

External Links